Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.54 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.50 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.50 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.50 |
| ▸ | MEN1 | O00255 | 1/20 | 0.49 |
| ▸ | TMEM97 | Q5BJF2 | 1/20 | 0.49 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.49 |
| ▸ | TSHR | P16473 | 2/20 | 0.49 |
| ▸ | DGAT1 | O75907 | 1/20 | 0.49 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.47 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.47 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.47 |
| ▸ | LMNA | P02545 | 2/20 | 0.46 |
| ▸ | PARP15 | Q460N3 | 1/20 | 0.46 |
| ▸ | PARP10 | Q53GL7 | 1/20 | 0.46 |
| ▸ | POLB | P06746 | 1/20 | 0.46 |
| ▸ | NPC1 | O15118 | 1/20 | 0.44 |
| ▸ | EGLN1 | Q9GZT9 | 1/20 | 0.44 |
| ▸ | HTT | P42858 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31737536 | 0.88 | ALDH1A1 (0.54) | ALDH1A1TDP1KMT2ASLC6A2SLC6A3 | |
| SCHEMBL522838 | 0.85 | ALDH1A1 (0.57) | ALDH1A1TDP1KMT2ASLC6A2SLC6A3 | |
| SCHEMBL18703864 | 0.85 | ALDH1A1 (0.57) | ALDH1A1TDP1KMT2ASLC6A2SLC6A3 | |
| SCHEMBL6832741 | 0.85 | TDP1 (0.59) | ALDH1A1TDP1KMT2ASLC6A2SLC6A3 | |
| SCHEMBL25087362 | 0.85 | ALDH1A1 (0.50) | ALDH1A1TDP1KMT2ASLC6A2SLC6A3 | |
| SCHEMBL18782372 | 0.84 | ALDH1A1 (0.64) | ALDH1A1TDP1KMT2ASLC6A2SLC6A3 | |
| SCHEMBL23457841 | 0.84 | TDP1 (0.67) | ALDH1A1TDP1KMT2ASLC6A2SLC6A3 | |
| SCHEMBL5463584 | 0.83 | GLA (0.46) | ALDH1A1KMT2AMEN1TMEM97SIGMAR1 | |
| SCHEMBL19479103 | 0.82 | ALDH1A1 (0.54) | ALDH1A1TDP1KMT2ASLC6A2SLC6A3 | |
| SCHEMBL3950165 | 0.82 | ALDH1A1 (0.54) | ALDH1A1TDP1KMT2ASLC6A2SLC6A3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 511 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12582634-B2 | Synthetic methods for preparation of 4-(2-chloro-4-methoxy-5-methylphenyl)-n-[(1S)-2-cyclopropyl-1-(3-fluoro-4-methylphenyl)ethyl]-5-methyl-n-prop-2-ynyl-1,3-thiazol-2-amine | NEUROCRINE BIOSCIENCES, INC. (US) | 2026-03-24 | — | — | US | claimed |
| US-20230286932-A1 | SYNTHETIC METHODS FOR PREPARATION OF 4-(2-CHLORO-4-METHOXY-5-METHYLPHENYL)-N-[(1S)-2-CYCLOPROPYL-1-(3-FLUORO-4-METHYLPHENYL)ETHYL]-5-METHYL-N-PROP-2-YNYL-1,3-THIAZOL-2-AMINE | NEUROCRINE BIOSCIENCES, INC. | 2023-09-14 | — | — | US | claimed |
| CN-115087647-A | Synthetic method for preparing 4- (2-chloro-4-methoxy-5-methylphenyl) -N- [ (1S) -2-cyclopropyl-1- (3-fluoro-4-methylphenyl) ethyl ] -5-methyl-N-prop-2-alkynyl-1, 3-thiazol-2-amine | 纽罗克里生物科学有限公司 | 2022-09-20 | — | — | CN | claimed |
| WO-2021111179-A1 | SYNTHETIC METHOD FOR PREPARATION OF 4-(2-CHLORO-4-METHOXY-5-METHYLPHENYL)-N-[(1S)-2-CYCLOPROPYL-1-(3-FLUORO-4-METHYLPHENYL)ETHYL]-5-METHYL-N-PROP-2-YNYL-1,3-THIAZOL-2-AMINE | NEUROCRINE BIOSCIENCES, INC. (US) | 2021-06-10 | — | — | WO | claimed |
| US-20260098029-A1 | KIF18A INHIBITORS | AMGEN INC. (US) | 2026-04-09 | — | — | US | disclosed |
| US-12582634-B2 | Synthetic methods for preparation of 4-(2-chloro-4-methoxy-5-methylphenyl)-n-[(1S)-2-cyclopropyl-1-(3-fluoro-4-methylphenyl)ethyl]-5-methyl-n-prop-2-ynyl-1,3-thiazol-2-amine | NEUROCRINE BIOSCIENCES, INC. (US) | 2026-03-24 | — | — | US | disclosed |
| US-20260062430-A1 | INHIBITORS OF KIF18A AND USES THEREOF | ACCENT THERAPEUTICS INC (US) | 2026-03-05 | — | — | US | disclosed |
| US-12509442-B2 | KIF18A inhibitors | AMGEN INC. (US) | 2025-12-30 | — | — | US | disclosed |
| US-12459932-B2 | KIF18A inhibitors | AMGEN INC. (US) | 2025-11-04 | — | — | US | disclosed |
| US-20250320224-A1 | NOVEL PAR-2 INHIBITORS | DOMAIN THERAPEUTICS (FR) | 2025-10-16 | — | — | US | disclosed |
| EP-3984523-B1 | CRF1 RECEPTOR ANTAGONIST, PHARMACEUTICAL FORMULATIONS AND SOLID FORMS THEREOF FOR THE TREATMENT OF CONGENITAL ADRENAL HYPERPLASIA | NEUROCRINE BIOSCIENCES INC (US) | 2025-09-03 | — | — | EP | disclosed |
| US-12391709-B2 | Inhibitors of KIF18A and uses thereof | ACCENT THERAPEUTICS, INC. (US) | 2025-08-19 | — | — | US | disclosed |
| US-6699860-B2 | ADRENERGIC BLOCKING AGENTS | BAYER PHARMACEUTICALS CORPORATION | 2004-03-02 | — | — | US | disclosed |
| EP-1389202-A1 | 2,6-SUBSTITUTED CHROMAN DERIVATIVES USEFUL AS BETA-3 ADRENORECEPTOR AGONISTS | Bayer Pharmaceuticals Corporation (US) | 2004-02-18 | — | — | EP | disclosed |
| US-6660752-B2 | Adrenergic blocking agents | BAYER PHARMACEUTICALS CORPORATION | 2003-12-09 | — | — | US | disclosed |
| EP-1343778-A2 | DI-SUBSTITUTED AMINOMETHYL CHROMAN DERIVATIVE BETA-3 ADRENORECEPTOR AGONISTS | Bayer Corporation (US) | 2003-09-17 | — | — | EP | disclosed |
| US-20030078260-A1 | 2,6-Substituted chroman derivatives useful as beta-3 adrenoreceptor agonists | BAYER PHARMACEUTICALS CORPORATION | 2003-04-24 | — | — | US | disclosed |
| US-20030078258-A1 | Di-substituted aminomethyl-chroman derivative beta-3 adrenoreceptor agonists | BAYER PHARMACEUTICALS CORPORATION | 2003-04-24 | — | — | US | disclosed |
| WO-2002085891-A1 | 2,6-SUBSTITUTED CHROMAN DERIVATIVES USEFUL AS BETA-3 ADRENORECEPTOR AGONISTS | BAYER PHARMACEUTICALS CORPORATION (US) | 2002-10-31 | — | — | WO | disclosed |
| WO-2002048134-A2 | DI-SUBSTITUTED AMINOMETHYL CHROMAN DERIVATIVE BETA-3 ADRENORECEPTOR AGONISTS | BAYER PHARMACEUTICALS CORPORATION (US) | 2002-06-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12509442-B2 | KIF18A inhibitors | KIF18A, KIF18B, KIFC1 | ALDH1A1 1067/4885TDP1 1527/4885KMT2A 379/4885 |
| US-20250320224-A1 | NOVEL PAR-2 INHIBITORS | F2RL1, F2R, F2RL3 | ALDH1A1 1534/4885TDP1 1631/4885KMT2A 2245/4885 |
| US-12391709-B2 | Inhibitors of KIF18A and uses thereof | KIF18A, KIF18B, KIF2C | ALDH1A1 1321/4885TDP1 741/4885KMT2A 1089/4885 |
| US-12459932-B2 | KIF18A inhibitors | KIF18A, KIF18B, KIF15 | ALDH1A1 1354/4885TDP1 1139/4885KMT2A 501/4885 |
| US-20030078260-A1 | 2,6-Substituted chroman derivatives useful as beta-3 adrenoreceptor agonists | ADRB3, ADRB2, ADRB1 | ALDH1A1 1358/4885TDP1 3719/4885KMT2A 4051/4885 |
| US-20230286932-A1 | SYNTHETIC METHODS FOR PREPARATION OF 4-(2-CHLORO-4-METHOXY-5-METHYLPHENYL)-N-[(1S)-2-CYCLOPROPYL-1-(3-FLUORO-4-METHYLPHENYL)ETHYL]-5-METHYL-N-PROP-2-YNYL-1,3-THIAZOL-2-AMINE | CYP21A2, NR5A1, HSD3B1 | ALDH1A1 700/4885TDP1 1221/4885KMT2A 1131/4885 |
| US-20260098029-A1 | KIF18A INHIBITORS | KIF18A, KIF18B, KIFC1 | ALDH1A1 1020/4885TDP1 1491/4885KMT2A 383/4885 |
| US-12582634-B2 | Synthetic methods for preparation of 4-(2-chloro-4-methoxy-5-methylphenyl)-n-[(1S)-2-cyclopropyl-1-(3-fluoro-4-methylphenyl)ethyl]-5-methyl-n-prop-2-ynyl-1,3-thiazol-2-amine | CYP21A2, CYP11B1, NR5A1 | ALDH1A1 525/4885TDP1 406/4885KMT2A 425/4885 |
| US-20030078258-A1 | Di-substituted aminomethyl-chroman derivative beta-3 adrenoreceptor agonists | ADRB3, ADRB1, ADRB2 | ALDH1A1 1696/4885TDP1 3902/4885KMT2A 3080/4885 |
| US-20260062430-A1 | INHIBITORS OF KIF18A AND USES THEREOF | KIF18A, KIF18B, KIF5B | ALDH1A1 1251/4885TDP1 852/4885KMT2A 448/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.